⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Synendos Therapeutics and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Synendos Therapeutics
↗Basel, Switzerland
Synendos Therapeutics is a clinical-stage neuroscience company based in Basel, Switzerland. The company focuses on developing a new class of small molecules known as Selective Endocannabinoid Reuptake Inhibitors (SERIs) to treat neuropsychiatric and neurological disorders by restoring the natural functioning of the endocannabinoid system.
Founded as a spin-off from the University of Bern, the company aims to address high unmet medical needs in conditions such as Generalized Anxiety Disorder (GAD) and Post-Traumatic Stress Disorder (PTSD). Their lead candidate, SYT-510, is currently in clinical development.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Founded:2019
Ownership:private
Status:operating
FUNDING
Stage:Series A
Total Raised:$26.2M
Investors:Kurma Partners, Sunstone Life Science Ventures, Ysios Capital, Bernina BioInvest, High-Tech Gründerfonds (HTGF)
PIPELINE
Stage:Phase 2
Lead Drug Stage:Phase 2
Modalities:Small molecule
Active Trials:1
Trial Phases:Phase 1: 1 | Phase 2: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:King's College London (Phase 2 clinical trial collaboration)
COMPETITION
Position:Emerging
LEADERSHIP
Key Executives:
Andrea Chicca - CEO and CSO
George Garibaldi - CMO
Scientific Founders:Andrea Chicca, Jürg Gertsch
Board Members:Jutta Heim (Chair), Simon Russell
LINKS
Website:synendos.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Synendos Therapeutics. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.